Personalizing cardiovascular disease prevention among breast cancer survivors

Current Opinion in Cardiology

Volumn 27, Issue 5, 2012, Pages 515-524

  Singla, Abhishek ^a   Kumar, Gautam ^b   Bardia, Aditya ^c  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

aspirin; breast cancer; cardiovascular risk; personalized medicine; prevention

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; AMIFOSTINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; AROMATASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CARNITINE; CARVEDILOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDARUBICIN; LAPATINIB; MELPHALAN; MITOXANTRONE; PACLITAXEL; PRENYLAMINE; RAZOXANE; TAMOXIFEN; TRASTUZUMAB;

ARTERIAL THROMBOEMBOLISM; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVOR; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; DIET THERAPY; DISEASE ASSOCIATION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTENSITY MODULATED RADIATION THERAPY; INTRADUCTAL CARCINOMA; PERSONALIZED MEDICINE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENCE RISK; REVIEW; SMOKING CESSATION; TISSUE DOPPLER IMAGING; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; PRIMARY PREVENTION; RISK FACTORS; SURVIVORS; UNITED STATES;

EID: 84865529155     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283570040     Document Type: Review

References (136)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
2. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009; 302:1685-1692.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
4. Bouchardy C, Rapiti E, Blagojevic S, et al. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 2007; 25:1858-1869. (Pubitemid 46854419)
5. Stewart S, MacIntyre K, Hole DJ, et al. More 'malignant' than cancer? Fiveyear survival following a first admission for heart failure. Eur J Heart Fail 2001; 3:315-322. (Pubitemid 32895839)
6. Collins TC, Petersen NJ, Menke TJ, et al. Short-term, intermediate-term, and long-term mortality in patients hospitalized for stroke. J Clin Epidemiol 2003; 56:81-87. (Pubitemid 36183319)
7. Askoxylakis V, Thieke C, Pleger ST, et al. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer 2010; 10:105.
8. Schonberg MA, Marcantonio ER, Ngo L, et al. Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol 2011; 29:1570-1577.
9. Patnaik JL, Byers T, DiGuiseppi C, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 2011; 13:R64.
10. Patnaik JL, Byers T, Diguiseppi C, et al. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 2011; 103:1101-1111.
11. CDC (2011) Heart disease and stroke prevention. http://cdc.gov/nccdphp/ publications/AAG/pdf/dhdsp.pdf. [Accessed 7 July 2012]
12. Bardia A, Arieas ET, Zhang Z, et al. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat 2012; 131:907-914.
13. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109:3122-3131.
14. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23:7820-7826. (Pubitemid 46657379)
15. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicininduced congestive heart failure. Ann Intern Med 1979; 91:710-717. (Pubitemid 10218041)
16. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25:3808-3815. (Pubitemid 47477254)
17. Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non- Hodgkin's lymphoma. J Clin Oncol 2008; 26:3159-3165.
18. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors:cardiac and pulmonary late effects. J Clin Oncol 2007; 25:3991-4008. (Pubitemid 47477279)
19. Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127-145.
20. Cvetkovic RS, Scott LJ. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 2005; 65:1005-1024. (Pubitemid 40667518)
21. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011; (6):CD003917.
22. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48:2258-2262. (Pubitemid 44855419)
23. Waldner R, Laschan C, Lohninger A, et al. Effects of doxorubicin- containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. J Cancer Res Clin Oncol 2006; 132:121-128.
24. Milei J, Marantz A, Ale J, et al. Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study. Cancer Drug Deliv 1987; 4:129-136. (Pubitemid 18043594)
25. Gallegos-Castorena S, Martinez-Avalos A, Mohar-Betancourt A, et al. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr Hematol Oncol 2007; 24:403-408. (Pubitemid 47301148)
26. Myers C, Bonow R, Palmeri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983; 10:53-55. (Pubitemid 13092606)
27. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244:707-712. (Pubitemid 19147683)
28. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182. (Pubitemid 17231334)
29. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684. (Pubitemid 41464706)
30. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2- positive breast cancer. N Engl J Med 2011; 365:1273-1283.
31. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672. (Pubitemid 41464705)
32. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354:809-820. (Pubitemid 43290919)
33. Spielmann M, Roche H, Delozier T, et al. Trastuzumab for patients withaxillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009; 27:6129-6134.
34. Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 2010; 21:2153-2160.
35. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23:2900-2902. (Pubitemid 46224107)
36. Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83:679-686. (Pubitemid 351810568)
37. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215-1221. (Pubitemid 34177427)
38. Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010; 28:3416-3421.
39. Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010; 28:3422-3428.
40. Valachis A, Mauri D, Polyzos NP, et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast 2011; 20:485-490.
41. Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 2004; 59:1-12. (Pubitemid 41327144)
42. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8:459-465. (Pubitemid 34546747)
43. Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002; 99:8880-8885. (Pubitemid 34693652)
44. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008; 31:459-467. (Pubitemid 351695459)
45. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792. (Pubitemid 32222155)
46. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25:3859-3865. (Pubitemid 47477261)
47. Bria E, Cuppone F, Fornier M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2008; 109:231-239. (Pubitemid 351644860)
48. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26:1231-1238.
49. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007; 369:29-36. (Pubitemid 46039831)
50. Levine MN. Trastuzumab cardiac side effects: only time will tell. J Clin Oncol 2005; 23:7775-7776. (Pubitemid 46657371)
51. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in nodepositive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23:7811-7819. (Pubitemid 46657378)
52. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006; 24:4107-4115. (Pubitemid 46622286)
53. Swedberg K, Cleland J, Cowie MR, et al. Successful treatment of heart failure with devices requires collaboration. Eur J Heart Fail 2008; 10:1229-1235.
54. Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. Target Oncol 2011; 6:189-195.
55. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28:3784-3796.
56. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451-1467.
57. Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 2008; 112:260-267.
58. Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and metaanalysis. J Natl Cancer Inst 2011; 103:1299-1309.
59. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799. (Pubitemid 46224178)
60. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
61. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30:117-124. (Pubitemid 37433402)
62. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006; 33:S26-S34. (Pubitemid 44634007)
63. Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 2010; 11:465-475.
64. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96:1788-1795. (Pubitemid 46912024)
65. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006; 42:3127-3139. (Pubitemid 44869016)
66. Halle M, Hall P, Tornvall P. Cardiovascular disease associated with radiotherapy: activation of nuclear factor kappa-B. J Intern Med 2011; 269:469-477.
67. Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12:447-453. (Pubitemid 24079884)
68. Hooning MJ, Aleman BM, van Rosmalen AJ, et al. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys 2006; 64:1081-1091.
69. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011; 378:1707-1716.
70. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000; 355:1757-1770.
71. Gutt R, Correa CR, Hwang WT, et al. Cardiac morbidity and mortality after breast conservation treatment in patients with early-stage breast cancer and preexisting cardiac disease. Clin Breast Cancer 2008; 8:443-448.
72. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99:365-375. (Pubitemid 47073480)
73. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol 2005; 6:557-565. (Pubitemid 41051933)
74. Giordano SH, Kuo YF, Freeman JL, et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005; 97:419-424. (Pubitemid 40528604)
75. Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005; 23:7475-7482. (Pubitemid 46291810)
76. Paszat LF, Mackillop WJ, Groome PA, et al. Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: a population-based study in Ontario, Canada. Int J Radiat Oncol Biol Phys 1999; 43:755-762.
77. Doyle JJ, Neugut AI, Jacobson JS, et al. Radiation therapy, cardiac risk factors, and cardiac toxicity in early-stage breast cancer patients. Int J Radiat Oncol Biol Phys 2007; 68:82-93. (Pubitemid 46613848)
78. Correa CR, Litt HI, Hwang WT, et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 2007; 25:3031-3037. (Pubitemid 47218049)
79. Pierce LJ, Butler JB, Martel MK, et al. Postmastectomy radiotherapy of the chest wall: dosimetric comparison of common techniques. Int J Radiat Oncol Biol Phys 2002; 52:1220-1230. (Pubitemid 34296482)
80. Hurkmans CW, Cho BC, Damen E, et al. Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation. Radiother Oncol 2002; 62:163-171. (Pubitemid 34286449)
81. Korreman SS, Pedersen AN, Josipovic M, et al. Cardiac and pulmonary complication probabilities for breast cancer patients after routine endinspiration gated radiotherapy. Radiother Oncol 2006; 80:257-262. (Pubitemid 44301538)
82. Hui SK, Das RK, Kapatoes J, et al. Helical tomotherapy as a means of delivering accelerated partial breast irradiation. Technol Cancer Res Treat 2004; 3:639-646. (Pubitemid 40023554)
83. Prosnitz RG, Chen YH, Marks LB. Cardiac toxicity following thoracic radiation. Semin Oncol 2005; 32:S71-S80.
84. Caudrelier JM, Morgan SC, Montgomery L, et al. Helical tomotherapy for locoregional irradiation including the internal mammary chain in left-sided breast cancer: dosimetric evaluation. Radiother Oncol 2009; 90:99-105.
85. Gauer T, Engel K, Kiesel A, et al. Comparison of electron IMRT to helical photon IMRT and conventional photon irradiation for treatment of breast and chest wall tumours. Radiother Oncol 2010; 94:313-318.
86. Coon AB, Dickler A, Kirk MC, et al. Tomotherapy and multifield intensitymodulated radiotherapy planning reduce cardiac doses in left-sided breast cancer patients with unfavorable cardiac anatomy. Int J Radiat Oncol Biol Phys 2010; 78:104-110.
87. Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010; 102:14-25.
88. Jurcut R, Wildiers H, Ganame J, et al. Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Support Care Cancer 2008; 16:437-445.
89. Ganame J, Claus P, Eyskens B, et al. Acute cardiac functional and morphological changes after anthracycline infusions in children. Am J Cardiol 2007; 99:974-977. (Pubitemid 46483288)
90. Bellenger NG, Grothues F, Smith GC, Pennell DJ. Quantification of right and left ventricular function by cardiovascular magnetic resonance. Herz 2000; 25:392-399. (Pubitemid 30470078)
91. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
92. Mosca L, Mochari H, Christian A, et al. National study of women's awareness, preventive action, and barriers to cardiovascular health. Circulation 2006; 113:525-534.
93. Patterson RE, Cadmus LA, Emond JA, Pierce JP. Physical activity, diet, adiposity and female breast cancer prognosis: a review of the epidemiologic literature. Maturitas 2010; 66:5-15.
94. Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer 2011; 105 (Suppl 1):S52-S73.
95. Ewertz M, Jensen MB, Gunnarsdottir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011; 29:25-31.
96. Sinicrope FA, Dannenberg AJ. Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol 2011; 29:4-7.
97. Fong DY, Ho JW, Hui BP, et al. Physical activity for cancer survivors: metaanalysis of randomised controlled trials. BMJ 2012; 344:e70.
98. Hoffman-Goetz L, Apter D, Demark-Wahnefried W, et al. Possible mechanisms mediating an association between physical activity and breast cancer. Cancer 1998; 83:621-628. (Pubitemid 28354488)
99. Friedenreich CM, Cust AE. Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects. Br J Sports Med 2008; 42:636-647.
100. Wilson DB, Porter JS, Parker G, Kilpatrick J. Anthropometric changes using a walking intervention in African American breast cancer survivors: a pilot study. Prev Chronic Dis 2005; 2:A16.
101. Abrahamson PE, Gammon MD, Lund MJ, et al. Recreational physical activity and survival among young women with breast cancer. Cancer 2006; 107:1777-1785. (Pubitemid 44582946)
102. Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:379-386. (Pubitemid 351272790)
103. Holmes MD, Chen WY, Feskanich D, et al. Physical activity and survival after breast cancer diagnosis. JAMA 2005; 293:2479-2486. (Pubitemid 40705729)
104. Irwin ML, Smith AW, McTiernan A, et al. Influence of pre and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol 2008; 26:3958-3964.
105. Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 2007; 25:2345-2351. (Pubitemid 46999205)
106. Sternfeld B, Weltzien E, Quesenberry CP Jr, et al. Physical activity and risk of recurrence and mortality in breast cancer survivors: findings from the LACE study. Cancer Epidemiol Biomarkers Prev 2009; 18:87-95.
107. Ibrahim EM, Al-Homaidh A. Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol 2011; 28:753-765.
108. Critchley JA, Capewell S. WITHDRAWN: smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2012; 2:CD003041.
109. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. World Health Organization: International Agency for Research on Cancer 2004; 83:5.
110. Miller MD, Marty MA, Broadwin R, et al. The association between exposure to environmental tobacco smoke and breast cancer: a review by the California Environmental Protection Agency. Prev Med 2007; 44:93-106. (Pubitemid 46188649)
111. Secretan B, Straif K, Baan R, et al. A review of human carcinogens: part E -tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009; 10:1033-1034.
112. Luo J, Margolis KL, Wactawski-Wende J, et al. Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study. BMJ 2011; 342:d1016.
113. Xue F, Willett WC, Rosner BA, et al. Cigarette smoking and the incidence of breast cancer. Arch Intern Med 2011; 171:125-133.
114. Johnson KC, Miller AB, Collishaw NE, et al. Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009). Tob Control 2011; 20:e2.
115. Pirie K, Beral V, Peto R, et al. Passive smoking and breast cancer in never smokers: prospective study and meta-analysis. Int J Epidemiol 2008; 37:1069-1079.
116. Rivera CM, Song J, Copeland L, et al. Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women. J Womens Health (Larchmt) 2012; 21:379-387.
117. Bardia A, Olson JE, Vachon CM, et al. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 2011; 126:149-155.
118. Luo T, Yan HM, He P, et al. Aspirin use and breast cancer risk: a metaanalysis. Breast Cancer Res Treat 2012; 131:581-587.
119. Boudreau DM, Gardner JS, Malone KE, et al. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 2004; 100:2308-2316. (Pubitemid 38657877)
120. Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol 2003; 56:280-285. (Pubitemid 36513491)
121. Cauley JA, Zmuda JM, Lui LY, et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 2003; 12:749-756. (Pubitemid 37361917)
122. Cauley JA, McTiernan A, Rodabough RJ, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 2006; 98:700-707. (Pubitemid 43821787)
123. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007; 120:833-843. (Pubitemid 46175404)
124. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005; 23:8606-8612. (Pubitemid 46211502)
125. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
126. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a metaanalysis. JAMA 2006; 295:74-80.
127. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011; 29:2645-2652.
128. Barron TI, Connolly RM, Sharp L, et al. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 2011; 29:2635-2644.
129. Powe DG, Voss MJ, Zanker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1:628-638.
130. Shah SM, Carey IM, Owen CG, et al. Does beta-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 2011; 72:157-161.
131. Sendur MA, Aksoy S, Yaman S, et al. Can all beta blockers improve the breast cancer survival? Breast 2012; 21:107-108.
132. Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11:627-636.
133. Bhaskaran K, Douglas I, Evans S, et al. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ 2012; 344:e2697.
134. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals. J Hypertens 2011; 29:623-635.
135. Mc Menamin UC, Murray LJ, Cantwell MM, Hughes CM. Angiotensinconverting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control 2012; 23:221-230.
136. Holmes MD, Chen WY, Li L, et al. Aspirin intake and survival after breast cancer. J Clin Oncol 2010; 28:1467-1472.